Overview
Dr. Leiman is an Associate Professor of Medicine and gastroenterologist specializing in esophageal diseases and swallowing disorders, such as eosinophilic esophagitis (EoE), motility disorders such as achalasia, and gastroesophageal reflux disease (GERD) as well as its associated complications including Barrett’s esophagus (BE). His busy clinical practice dovetails with his academic focus on health services research, including patient outcomes and clinical quality measurement. He is also a PI for several ongoing multicenter clinical trials investigating novel therapies for EoE and GERD.
Dr. Leiman has mentored numerous medical students, residents, and GI fellows on research and quality improvement projects resulting in research awards, presentations at national meetings, and peer-reviewed publications.
Current Appointments & Affiliations
Recent Publications
AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus.
Journal Article Gastroenterology · November 2025 BACKGROUND & AIMS: Barrett's esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC). Endoscopic surveillance has been proposed for early detection of BE-related neoplasia and reducing EAC mortality. This clinical practice guid ... Full text Link to item CiteAGA Clinical Practice Guideline on Management of Gastroparesis.
Journal Article Gastroenterology · October 2025 BACKGROUND & AIMS: Gastroparesis is a complex gastric motility disorder characterized by nausea, vomiting, and other symptoms associated with a delay in gastric emptying in the absence of mechanical obstruction. Variations in diagnostic testing and limited ... Full text Link to item CiteEsophageal Expert Development of a Preliminary Question Prompt List for Adults With Eosinophilic Esophagitis: A Modified Delphi Study.
Journal Article J Clin Gastroenterol · July 1, 2025 BACKGROUND: Question prompt lists (QPLs) are structured sets of disease-specific questions intended to encourage question-asking by patients and enhance patient-physician communication. To date, an EoE-specific QPL has not been developed for EoE patients. ... Full text Link to item CiteRecent Grants
TARGET-GASTRO - GI-02 Pro00114153 Longitudinal, observational, non-interventional study of FDA-approved medications and other therapies used in usual clinical practice.
Clinical TrialPrincipal Investigator · Awarded by TARGET PharmaSolutions, Inc. · 2024 - 2038Dupixent Registry R668-EE-2328 EDESIA Pro00117064
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2025 - 2030A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis. Celldex_CDX0159-08_Pro00112764
Clinical TrialPrincipal Investigator · Awarded by Celldex Therapeutics, Inc. · 2023 - 2026View All Grants